We’ve initiated dosing in the acute myeloid leukemia (AML) cohort of our ongoing Phase 1 study of STX-0712 (NCT06950034), expanding its evaluation to patients with relapsed/refractory monocytic or monocytic-predominant AML. Learn more: cdn.prod.website-files.com/6…. #oncology

#BloodCancerAwarenessMonth may be winding down, but opportunities to support the blood cancer community continue this fall. On Oct. 15, we’ll join @BloodCancerUtd for Light The Night Boston, where we’re proud to be a sponsor for the third consecutive year: lightthenight.org/events/bos…

This #BloodCancerAwarenessMonth, we recognize the patients, families and communities affected by blood cancers. Find information and support from our partners at @BloodCancerUtd: bloodcancerunited.org/ Learn about our work in #CMML and #AML: solutherapeutics.com/#oncolo…

Not all immune cells play the same role in disease. As researchers continue to better understand the immune cell subsets that contribute to disease, new opportunities are emerging to explore more targeted investigational approaches. Learn more: solutherapeutics.com/

Every 3 minutes, someone in the U.S. is diagnosed with blood cancer. This #BloodCancerAwarenessMonth, we recognize those affected and the researchers, clinicians and advocates moving the field forward. Learn about our work in blood cancer: solutherapeutics.com/#oncolo…

We are deeply saddened by the loss of Peter Barton Hutt, a valued member of our Board and pioneering leader in food and drug law. We are grateful for his wisdom, guidance and contributions to Solu. Our thoughts are with his family, friends and colleagues.

Did you know Blood Cancer Awareness Month begins next week? Follow our partner @BloodCancerUtd throughout September for educational resources, patient stories, and ways to support the blood cancer community: bloodcancerunited.org/

New discoveries in disease biology continue to uncover opportunities for more targeted therapeutic approaches. Learn how we're advancing investigational CyTAC™-based programs across oncology, inflammation, and immunology: solutherapeutics.com/

An estimated 8% of the U.S. population has an autoimmune disease, highlighting the need for continued innovation in immunology. We're advancing investigational CyTAC™-based programs for autoimmune and inflammatory diseases. Learn more: solutherapeutics.com/#immuno…

A 2025 study found that people with blood cancer have 2x the risk of developing skin cancer compared to the general population. Practice sun safety this summer with these helpful tips from @BloodCancerUtd: bloodcancerunited.org/resour…

Our team spends a lot of time solving complex problems together. This week, we took those skills beyond the lab and into the escape rooms at @TrapologyBoston. Thanks for a fun and memorable team-building experience!

Mast cells are increasingly recognized as drivers of immunological and inflammatory disorders, yet no approved therapies are designed to achieve rapid, deep, and selective mast cell depletion. We're exploring new approaches through our CyTAC™ platform: solutherapeutics.com/#immuno…

Many drug targets remain difficult to access through traditional approaches. Our CyTAC™ platform combines small molecules & antibodies designed to target cell surface proteins aiming to unlock possibilities across #oncology, #immunology, & #inflammation: solutherapeutics.com/#platfo…

We recently held a pre-BOD meeting dinner at Fenway Park, bringing together the Solu team alongside our BOD and Board Observers. It was a great evening to celebrate our progress and spend some time with the Red Sox mascot, Wally. Thank you to everyone who joined!

We want to thank Amrin Jenny for all of her contributions to our research during her Spring Research Co-Op term. We wish her all the best in the next chapter of her scientific journey!

That’s a wrap on #BIO2026! Our CBO Michael Boretti spent the week in SD connecting with attendees while sharing more about our work in #oncology, #immunology, and #inflammation. We appreciate the insights and look forward to continuing the conversation. solutherapeutics.com/

June is #NationalCancerSurvivorsMonth. Survivorship is about more than treatment. Ongoing care, monitoring, and access to resources are essential. As part of our commitment to advancing research for cancer, we're proud to support @BloodCancerUtd: bloodcancerunited.org/blood-…

June is #AMLAwarenessMonth. According to @AmericanCancer, more than 22,000 people in the U.S. are expected to be diagnosed with #AML in 2026. We’re advancing hematologic malignancy research through our CyTAC™ platform, with potential expansion into #AML: solutherapeutics.com/#oncolo…

#ICYMI: Last month, our lead investigational CyTAC™ program for relapsed or refractory #CMML received FDA Fast Track designation. Read recent coverage in Rare Cancer News (@bionewsservices): rarecancernews.com/news/solu…

Next week, our CBO Michael Boretti will be at #BIO2026 in San Diego, connecting with partners, investors, and innovators across the global biotech community to discuss our work in #oncology, #immunology, and #inflammation. Learn more: convention.bio.org/